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Background: Synovial sarcoma account for approximately 10 % of all soft-tissue tumors and occur most frequently
in young adults. A specific translocation in this sarcoma induces fusion of the SYT gene on chromosome 18 to the
SSX genes on chromosome X, leading to proliferation of the tumor cells. The need for non-invasive biomarkers
indicating recurrence and activity of this disease has sparked research into short non-coding RNA known as
microRNA (miRNA).
Methods: Blood samples of patients with active synovial sarcoma and of synovial sarcoma patients in complete
remission as well as of healthy donors and patients with active leiomyosarcoma, MPNST, Ewing sarcoma and
liposarcoma were collected. Whole blood RNA was extracted and samples of patients with active synovial sarcoma
and of healthy donors were analyzed using an Affymetrix GeneChip miRNA Array v. 4.0. qRT-PCR was carried out to
confirm a panel of miRNAs which where differentially expressed in the miRNA array. This miRNA-panel was further
evaluated in patients with synovial sarcoma in complete remission and patients with active leiomyosarcoma,
MPNST, Ewing sarcoma and liposarcoma as well as in an independent cohort of synovial sarcoma patients.
Results: Unsupervised hierarchical clustering of the miRNA arrays separated patients with active synovial sarcoma
from healthy controls. A panel of seven miRNAs (miR-99a-5p, miR-146b-5p, miR-148b-3p, miR-195-5p, miR-223-3p,
miR-500b-3p and miR-505-3p) was further validated by qRT-PCR to be significantly upregulated in synovial sarcoma
patients. Moreover, most of the analyzed miRNAs were shown to be significantly upregulated in synovial sarcoma
patients compared to leiomyosarcoma, MPNST, Ewing sarcoma and liposarcoma patients. Validation of the miRNA
panel in an independent cohort of synovial sarcoma patients confirmed higher expression levels compared to
healthy controls and patients in complete remission.
Conclusion: Our results have identified a specific whole blood miRNA signature that may serve as an
independent biomarker for the diagnosis of local recurrence or distant metastasis of synovial sarcoma. It even
distinguishes synovial sarcoma from other sarcoma subtypes, thus potentially serving as a specific biomarker for
synovial sarcoma.
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Soft tissue sarcoma constitute a heterogeneous group of
malignant tumors of mesenchymal origin, showing fre-
quent local recurrence and distant metastasis [1, 2]. Syn-
ovial sarcoma account for approximately 10 % of all
soft-tissue sarcoma and most frequently develop in the
extremity of young adults [3]. The cytogenetically de-
fined translocation t(X; 18) (p11.2; q11.2) found in syn-
ovial sarcoma results in the fusion of the SYT gene on
chromosome 18 to either SSX1, SSX2 or SSX4 on
chromosome X, resulting in the formation of a SS18-
SSX1, SS18-SSX2 or the rare SS18-SSX4 fusion tran-
script [4–7], which allow a very specific and sensitive
molecular diagnosis of synovial sarcoma by fluorescence
in situ hybridization (FISH) or quantitative and conven-
tional reverse transcription-polymerase chain reaction
(RT-PCR) of tumor tissue [8]. However, diagnosis of
local recurrence or distant metastasis of synovial sar-
coma is restricted to magnetic resonance imaging (MRI),
computed tomography (CT) and biopsy [2]. Therefore,
the need for non-invasive biomarkers indicating recur-
rence and activity of this disease has sparked research
into microRNAs (miRNAs), which are small, non-coding
molecules of about 22 nucleotides in length. MiRNAs
regulate the expression of target genes through mRNA
degradation and translation inhibition [9], and have been
shown to serve as potential biomarkers in different ma-
lignancies [10–12].
Interestingly, many poorly differentiated tumors can
be successfully classified using miRNA expression pro-
files whereas messenger RNA profiles may be rather in-
accurate when applied to the same samples [13]. Recent
publications show that sarcoma tissue of different histo-
logical subtypes show distinct miRNA expression pro-
files [14–16]. However, few studies concentrate on
peripheral blood miRNA profiling. Miyachi et al. de-
tected miR-206 to be significantly upregulated in pe-
ripheral blood of patients with rhabdomyosarcoma
compared to patients with non-rhabdomyosarcoma tu-
mors [17], thus showing that miRNA expression levels
may be used to differentiate between different tumors.
Furthermore, the detection of miRNAs in peripheral
blood may serve as a non-invasive method for diagnosis
of metastasis or local tumor recurrence, possibly im-
proving survival rates due to earlier detection of sarcoma
recurrence as well as making follow-up more eco-
nomical. Therefore, we performed a comprehensive
microarray-based miRNA screen of whole blood RNA of
synovial sarcoma patients compared to healthy controls,
followed by validation of deregulated miRNAs using
quantitative Real-Time polymerase chain reaction (qRT-
PCR), assessing differences in patients with active
synovial sarcoma compared to healthy controls, pa-
tients with synovial sarcoma in complete remissionand patients with active leiomyosarcoma, malignant
peripheral nerve sheath tumor (MPNST), Ewing sar-
coma and liposarcoma.
Results and discussion
The screening cohort of patients with active synovial
sarcoma (n = 5) as analyzed in a microarray as well as
the independent validation cohort of synovial sarcoma
patients (n = 3) did not differ significantly from the
healthy controls (n = 5), synovial sarcoma in complete
remission (n = 10) and active leiomyosarcoma (n = 5),
MPNST (n = 3), Ewing sarcoma (n = 3) and liposarcoma
(n = 6) group concerning age, BMI, hemoglobin (Hb)
level, platelet count and leukocyte count (Additional
file 1 and Additional file 2). Two patients with active syn-
ovial sarcoma presented the SS18-SSX2 fusion gene
phenotype, while five presented the more common
SS18-SSX1 phenotype [6, 18]. Tumor tissue of one patient
was not available for analysis. Information regarding dis-
ease and therapy status of sarcoma patients is depicted in
Additional file 3. Whole blood RNA from patients with ac-
tive synovial sarcoma (n = 5) and healthy controls (n = 5)
was analyzed by Affymetrix miRNA 4.0 Arrays. Micro-
array data are available in the ArrayExpress database
(www.ebi.ac.uk/arrayexpress) under accession number
E-MTAB-3273 (http://www.ebi.ac.uk/arrayexpress/ex-
periments/E-MTAB-3273). Hierarchical clustering of
all covered human mature miRNAs and human pre-
miRNAs separated sarcoma samples from control sam-
ples (Fig. 1a). Following hierarchical clustering, the
array results were narrowed down to deregulated miR-
NAs with a fold change > |3.0|, a p-value <0.005, a q-
value (false discovery rate (FDR)-corrected p-value)
[19] <0.2 and a similar deregulation of related miRNAs
with the same base sequence throughout the array. Of
the ten miRNAs, which met these criteria (miR-99a-5p,
miR-146b-5p, miR-148b-3p, miR-183-3p, miR-195-5p,
miR-223-3p, miR-500b-3p, miR-505-3p, miR-589-5p and
miR-1225-5p), nine miRNAs showed an increased expres-
sion in tumor patients and one miRNA was decreased
(Table 1). Unsupervised hierarchical clustering of this
panel could again separate sarcoma patients from healthy
controls (Fig. 1b).
Subsequently, seven miRNAs were further validated by
qRT-PCR (Fig. 2): miR-99a-5p, miR-146b-5p, miR-148b-
3p, miR-195-5p, miR-223-3p, miR-500b-3p and miR-
505-3p. All seven miRNAs were significantly upregulated
in the screening cohort of patients with synovial sar-
coma (n = 5) compared to healthy controls (n = 5).
Moreover, five of the analyzed miRNAs were shown to
be significantly upregulated in the screening cohort of
active synovial sarcoma patients compared to patients
with active leiomyosarcoma (n = 5): miR-146b-5p, miR-
148b-3p, miR-223-3p, miR-500b-3p and miR-505-3p.
total of 4603 
miRNAs
B A 
Fig. 1 Hierarchical clustering separated sarcoma samples from control samples. a. Hierarchical clustering of all covered human mature miRNAs
and human pre-miRNAs. b. Hierarchical clustering of the 10 miRNAs meeting the following criteria: Fold change > |3.0|, p-value <0.005,
q-value <0.2 and a similar deregulation of related miRNAs with the same base sequence throughout the array
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deregulated (Fig. 2). Comparing the screening cohort of
active synovial sarcoma patients to patients with active
MPNST (n = 3), six of the analyzed miRNAs were shown
to be significantly upregulated: miR-99a-5p, miR-146b-
5p, miR-148b-3p, miR-223-3p, miR-500b-3p and miR-
505-3p. MiR-195-5p was not significantly deregulated
(Fig. 2). Analyzing active synovial sarcoma patients and
patients with active Ewing sarcoma (n = 3), five of theTable 1 MiRNAs with a fold change of > |3.0|, a p-value <0.005,
a q-value <0.2 and a similar deregulation of related miRNAs with
the same base sequence throughout the array
Transcript ID Sarcoma Sarcoma Control Control Fold
ChangeMean STD Mean STD
upregulated
hsa-miR-146b-5p 4.83 0.85 1.81 0.65 8.10
hsa-miR-99a-5p 4.51 0.35 1.92 1.17 6.03
hsa-miR-223-3p 10.50 0.66 8.25 0.91 4.77
hsa-miR-148b-3p 6.68 0.82 4.58 0.74 4.29
hsa-miR-500b-3p 4.28 0.65 2.28 0.82 4.01
hsa-miR-183-3p 6.83 0.46 4.97 0.90 3.62
hsa-miR-589-5p 4.84 0.57 3.06 0.82 3.43
hsa-miR-505-3p 3.73 0.67 1.96 0.61 3.40
hsa-miR-195-5p 2.96 0.43 1.24 0.46 3.30
downregulated
hsa-miR-1225-5p 4.76 0.64 6.89 0.64 −4.39analyzed miRNAs were shown to be significantly upreg-
ulated: miR-146b-5p, miR-148b-3p, miR-223-3p, miR-
500b-3p and miR-505-3p. MiR-99a-5p and miR-195-5p
were not significantly deregulated. Compared to patients
with active liposarcoma (n = 6), all seven analyzed miR-
NAs were shown to be significantly upregulated (Fig. 2).
These results suggest that the detection of these miR-
NAs in whole blood of synovial sarcoma patients pro-
vides a non-invasive way to detect distant metastasis or
local recurrence and this “liquid biopsy” could poten-
tially develop into a further keystone of tumor diagnosis
and staging. We therefore validated the expression levels
of all seven miRNAs by qRT-PCR in an independent co-
hort of active synovial sarcoma patients (n = 3): Five of
the analyzed miRNAs were shown to be significantly
upregulated when compared to the group of healthy do-
nors (miR-146b-5p, miR-148b-3p, miR-195-5p, miR-
500b-3p and miR-505-3p). MiR-99a-5p and miR-223-3p
were also expressed in higher quantities, however differ-
ences were not statistically significant (Fig. 3). Expres-
sion of this miRNA panel was further analyzed in
samples of synovial sarcoma patients in complete remis-
sion (n = 10). All seven miRNAs were significantly up-
regulated in the independent cohort of active synovial
sarcoma patients compared to patients with synovial sar-
coma in complete remission (Fig. 3)
To exclude a bias of fundamental expression levels of
miRNAs among the individual patients with synovial sar-
coma and to illustrate the change of miRNA expression at
Fig. 2 MiRNA-expression in patients with active synovial sarcoma compared to healthy donors and patients with active leiomyosarcoma, MPNST,
Ewing sarcoma and liposarcoma. a. miR-99a-5p. b. miR-146b-5p. c. miR-148b-3p. d. miR-195-5p. e. miR-223-3p. f. miR-500b-3p. g. miR-505-3p
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Fig. 3 MiRNA-expression in the independent cohort (IC) of patients with active synovial sarcoma compared to healthy donors and patients with
synovial sarcoma in remission. a. miR-99a-5p. b. miR-146b-5p. c. miR-148b-3p. d. miR-195-5p. e. miR-223-3p. f. miR-500b-3p. g. miR-505-3p
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pair analysis in two individual sarcoma patients. Patient 1
initially presented with localized disease of the lower ex-
tremity. The miRNA-expression before surgical resection
of the tumor as well as two weeks, three months and ten
months after complete surgical removal of the tumor was
analyzed. The miRNA expression levels decreased rapidly
after tumor resection (Fig. 4). Patient 2 was part of the
synovial sarcoma in remission cohort at first with unsuspi-
cious miRNA levels. However, she developed pulmonary
metastases four months after the initial blood withdrawal.
The 2nd blood withdrawal was carried out 5 month after
the 1st blood withdrawal. At this time, the miRNAFig. 4 Change in miRNA-expression at remission as well as when presentin
1 initially presented with localized disease of the lower extremity. miRNA le
complete tumor resection. b. Patient 2 was in complete remission but develoexpression levels were significantly elevated when com-
pared to their expression at the time of remission (Fig. 4).
Thus, by performing a matched-pair analysis in these two
individual sarcoma patients, we were able to illustrate the
downregulation of miRNA expression at remission as well
as the upregulation of the presented miRNAs in reoccur-
ring active disease.
In summary, the detected miRNAs might provide sen-
sitive biomarkers to distinguish patients with active syn-
ovial sarcoma from healthy controls and patients in
complete remission by a simple and non-invasive blood
test. They might also be useful to distinguish synovial
sarcoma from other soft tissue sarcoma subtypes.g active disease in two individual synovial sarcoma patients. a. Patient
vels were recorded 1 day before surgery and at three time-points after
ped pulmonary metastasis 4 months after the initial blood withdrawal
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be altered by differences in circulating blood cells. In
our two cohorts, patients with active synovial sarcoma
did not differ significantly from the healthy controls,
synovial sarcoma in complete remission and active leio-
myosarcoma, MPNST, Ewing Sarcoma and liposarcoma
group concerning age, BMI, hemoglobin-level, platelet
count and leukocyte count (Additional file 1 and
Additional file 2), thus showing that different miRNA
expression in the patient groups evaluated was not due
to changes in cell populations such as cancer- and
chemotherapy-induced anemia. Furthermore, miRNA-
expression levels did not differ whether patients received
anticoagulation or chemotherapy. The fact that the pa-
tient receiving radiotherapy showed the lowest miRNA-
expression levels of all active synovial sarcoma patients
for most of the detected miRNAs (Additional file 4) was
probably due to the fact that this patient was also the
only patient presenting with localized disease, thus sug-
gesting that high miRNA expression levels reflect the
dissemination or possibly the activity of the disease.
When analyzing miRNA expression levels in synovial
sarcoma tissue and whole blood of patients with active
synovial sarcoma, the majority of the detected miRNAs
did not show correlations with SS18-SSX1 and 2 fusion
gene phenotypes (Additional file 5). However, the sample
number in these subgroups are to low to allow for a
valid conclusion. A major advantage of blood sample
collection in PAXgene Blood RNA Tubes is the immedi-
ate stabilization of intracellular RNA, thus preserving
the gene expression profile for reliable downstream gene
expression analysis. Without immediate stabilization,
degradation of RNA and upregulation or downregulation
of transcripts may alter the results of further analysis.
Furthermore, blood samples collected in PAXgene Blood
RNA Tubes can be safely stored or transported at room
temperature for up to 72 h and at −20 °C or −70 °C
for at least 50 months. This might reduce pre-analytical
errors and facilitate future multi-centre studies, as imme-
diate processing, which is for example needed for the de-
tection of plasma biomarkers, is not necessary, thus
avoiding potential changes in miRNA levels by different
processing conditions [20].
Keller et al., analyzing 454 whole blood samples col-
lected in PAXgene Blood RNA Tubes from human indi-
viduals with different cancers or non-cancer diseases,
were able to predict the correct disease in 67.45 % of all
individuals by their miRNA expression profiles. Further-
more, they were able to distinguish lung cancer from
chronic obstructive pulmonary disease (COPD) with an
accuracy of 91.7 %, thus providing support for the feasi-
bility of peripheral whole blood miRNA expression pat-
terns in spite of the fact that changes in cell populations
may affect overall miRNA profiles. They also found thatonly a few of the miRNAs deregulated in blood were
also previously reported as deregulated in solid tissues
derived from individuals with the same diseases [21],
which explains why the miRNAs found to be deregu-
lated in whole blood of synovial sarcoma patients in our
study did not correlate with previous findings of deregu-
lated miRNAs such as miR-183, miR-200b∗, miR-375,
[16] let-7e, miR-99b, and miR-125-3p, [18] miR-200b,
miR-200c and miR-141 [15] in synovial sarcoma tissue.
This might be due to the fact that the miRNA expres-
sion patterns found in whole blood depict the miRNA
expression patterns of peripheral blood mononuclear
cells (PBMC) rather than the miRNA expression pat-
terns of circulating tumor cells, as Mookherjee et al.
proved in their study [22]. Furthermore, Leidinger et al.
showed that especially the miRNA signature of cells of
the innate immune system allowed separation between
lung cancer patients and healthy controls, however
pointing out that cancer-specific miRNA expression of
whole blood samples are not determined by a single cell
type but influenced by other blood constituents such as
platelets or erythrocytes [23]. These studies point out
that the miRNA signature of synovial sarcoma detected
in our study represents a response of the innate immune
system to the tumor rather than the miRNA expression
profile of the tumor itself, thus explaining why none of
the presented miRNAs match the highly expressed miR-
NAs in synovial sarcoma tissues as described by Fujiwara
et al. [24], Hisaoka et al. [18] and Renner et al. [16]. This
is further suggested by the following findings: When
comparing the expression of the detected miRNAs in
whole blood RNA of patients with active synovial sar-
coma with the corresponding tumor tissue (n = 7), we
found that most miRNAs were significantly higher
expressed in whole blood RNA of patients with active
synovial sarcoma (Fig. 5). MiR-99a-5p was the only
miRNA being higher expressed in synovial sarcoma tis-
sue than in whole blood. Comparing the miRNA expres-
sion levels in synovial sarcoma tissue (n = 7) with
healthy skeletal muscle (n = 5), we found no significantly
different expression of most of the detected miRNAs
(Fig. 5). Only MiR-223-3p was significantly higher
expressed in healthy skeletal muscle tissue (Fig. 5e).
When comparing the miRNA expression levels of lym-
phocytes (Jurkat; human T lymphocyte cell line) and
monocytes (THP-1; human acute monocytic leukemia
cell line) to synovial sarcoma cells (SYO-1 und 1273/99
cell line), we found that most miRNAs were significantly
higher expressed in human lymphocytes compared to
SYO-1 and 1273/99 synovial sarcoma cells and human
monocytes compared to SYO-1 and 1273/99 synovial
sarcoma cells (Additional file 6). Interestingly, miR-99a-
5p is the only miRNA being higher expressed both in
synovial sarcoma tissue compared to whole blood cells
Fig. 5 Comparison of whole blood miRNA expression levels of patients with active synovial sarcoma to corresponding synovial sarcoma tissue,
healthy skeletal muscle, Jurkat (human T-lymphocyte cell line), THP-1 cells (human acute monocytic leukemia cell line) and synovial sarcoma cells
(SYO-1 und 1273/99 cell lines). a. miR-99a-5p. b. miR-146b-5p. c. miR-148b-3p. d. miR-195-5p. e. miR-223-3p. f. miR-500b-3p. g. miR-505-3p
Fricke et al. Molecular Cancer  (2015) 14:151 Page 8 of 13
Fricke et al. Molecular Cancer  (2015) 14:151 Page 9 of 13(Fig. 5a) and synovial sarcoma cells compared to THP-1
and Jurkat cells (Additional file 6A), thus indicating that
the high expression levels of miR-99a-5p in synovial sar-
coma patients might not result from a miRNA expres-
sion shift of peripheral blood cells but might actually be
related to the tumor itself. However, miR-99a-5p shows
overlapping expression values in whole blood of patients
with active synovial sarcoma compared to the different
control groups (Figs. 2 and 3), thus it is not an ideal bio-
marker for synovial sarcoma. Furthermore, it was shown
that human macrophages transfer miR-223 to hepatocar-
cinoma cells through intercellular contact, leading to de-
creased expression of stathmin-1 and insulin-like growth
factor-1 receptor and decreased proliferation of tumor
cells [25], which adds to the point that the detected up-
regulation of miR-223-3p in whole blood cells might pri-
marily be a defense of circulating mononuclear cells
against the proliferation of synovial sarcoma.
Interestingly, we found that four of the detected seven
miRNAs seem to interact with the nuclear factor kappa
B pathway (NF- κB), thus possibly playing an important
role in toll like and cytokine receptor signaling. MiRNAs
are well described regulators of the immune response
[26]. The expression of miR-146b has been both shown
to be upregulated by inflammation-related induction of
NF-κB through a MyD88-dependent pathway, and
also downregulating TNF receptor-associated factor 6
(TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1),
thus reducing the activity of the pathway by a negative
feedback regulation loop and maintaining the balance
of toll like and cytokine receptor signaling [27]. In
consistency with this study, Hulsmans et al. showed
that silencing of miR-146b-5p resulted in more NFκB
p65 DNA binding activity and TNFα. Moreover, low
levels of miR-146b-5p in monocytes of obese persons
have been shown to be associated with increased mi-
tochondrial reactive oxygen species (ROS) [28], thus
showing that miR-146b inhibits NF-κB – mediated in-
flammation. An upregulation of miR-146b-5p might
thus reflect an immune evasion of the tumor, leading
to increased tumor proliferation and progression. MiR-
195 also seems to interact with NF-κB, as it was
shown to decrease the expression of multiple NF-κB
downstream effectors [29]. Another of the NFκ-B re-
lated miRNAs is miR-223; as the transcriptional activ-
ity of miR-223 promoter was shown to be activated by
Notch and NF-κB [30]. Finally, miR-500 was shown to
induce gastric cancer cell proliferation and tumorigen-
icity by activating NF-κB. [31]. Thus, although finding
the exact biological significance of the miRNAs in
tumorigenesis of synovial sarcoma is a complex matter,
it seems that the miRNAs detected in our study control
various activities of the immune system by interacting
with different pathways such as the NFκ-B signalingpathway. This further underlines our hypothesis that the
detected miRNA expression levels reflect changes of the
immune system as a defense to tumor progression as
well as immune evasion mechanisms of the tumor.
Biomarkers for synovial sarcoma are urgently needed to
identify patients with local recurrence and metastatic dis-
ease, as imaging studies are often inconclusive. Although
validated miRNAs were not always significantly different
in patients with active disease compared to the different
control groups, miR-146b-5p, miR-500b-3p and miR-505-
3p allow discrimination of patients of active synovial
sarcoma patients from the different control groups,
showing clear cut-off-values at approximately 18.5
(miR-146b-5p), 17.5 (miR-500b-3p) and 11.5 (miR-
505-3p) 2-ΔΔCt; while miR-99-5p, miR-148b-3p, miR-
195-5p and miR-223-3p show overlapping expression
values. These miRNAs are promising candidates as
diagnostic biomarkers for synovial sarcoma, poten-
tially allowing the detection of local recurrence or
distant metastasis by a simple blood test: A rise of
these miRNAs beyond the cut-off value - while ini-
tially lying underneath the cut-off value following
complete removal of the tumor - might indicate local
recurrence or distant metastasis, as shown in Fig. 4b
(Patient 2). Moreover, these miRNAs could be applied
in order to distinguish between synovial sarcoma and
other types of sarcoma, which may be of therapeutic
importance if chemosensitive sarcoma such as the
rare extraosseous Ewing’s sarcoma with spindle cell
sarcoma-like pattern, often showing histological over-
lap with synovial sarcoma [32], are considered in dif-
ferential diagnosis. Although our results proved to be
highly significant, the main limitation of this study
consists in the low number of patients within the dif-
ferent study groups. Nonetheless, one has to take into
account that soft tissue sarcoma is a rare malignancy
which is furthermore divided into a variety of differ-
ent subtypes, thus making the collection of a large
number of patients within one study group difficult.
We preferred to identify a miRNA panel in a small
group of patients with synovial sarcoma as an initial
“proof of concept” rather than including a large num-
ber of patients with different sarcoma subtypes. As
synovial sarcoma is characterized by the presence of
the SS18-SSX fusion gene, which can be detected by
fluorescence in situ hybridization (FISH) of tumor
tissue, this sarcoma subtype can be specifically diag-
nosed without the risk of being confounded with
other sarcoma subtypes. Through this approach, we
achieved highly significant miRNA array and qRT-
PCR results and a clear separation of sarcoma sam-
ples from control samples by hierarchical clustering.
The fact that the miRNA signature established in this
pilot study even distinguishes synovial sarcoma from
Fricke et al. Molecular Cancer  (2015) 14:151 Page 10 of 13leiomyosarcoma, MPNST, Ewing sarcoma and liposar-
coma samples further elucidates the specificity of our
results.
Further studies are warranted to validate the panel of
deregulated miRNAs in a larger cohort of independent
synovial sarcoma patients and to identify miRNA signa-
tures of other sarcoma subtypes. Moreover, the existing
group of patients with synovial sarcoma in complete re-
mission needs to be closely monitored in order to evalu-
ate a possible rise of the established miRNAs with local
recurrence or distant metastasis.
Conclusion
Our results have identified a specific whole blood miRNA
signature that may serve as an independent biomarker for
the diagnosis of local recurrence or distant metastasis of
synovial sarcoma and that even distinguishes synovial sar-
coma from other histological sarcoma subtypes.
Methods
Study population
All patients included in the study were patients receiving
treatment from specialists in the interdisciplinary tumor
board of the Comprehensive Cancer Center Freiburg
(CCCF). Patients with a history of cancer other than sar-
coma or any type of systemic inflammatory disease or
autoimmune disorder were excluded. The control group
included healthy adults matched to the active synovial
sarcoma group in terms of age, sex and body mass index
(BMI). Diagnosis of synovial sarcoma, leiomyosarcoma,
MPNST, Ewing sarcoma and liposarcoma was confirmed
by two independent pathologists.
Ethics, consent and permissions
Signed informed consent was obtained from all partici-
pants, allowing analysis of blood samples and all clinical
data. The Ethics Committee of the Albert-Ludwigs-
University of Freiburg, Germany, approved the study.
The design and performance of the study is in accord-
ance with the Declaration of Helsinki.
Blood sampling
All blood samples were collected by puncture of the
antecubital vein without tourniquet through a 20-gauge
needle. The first 3 ml of blood were discarded. Each
2.5 ml of whole blood were collected and stabilized in
PAXgene Blood RNA Tubes (PreAnalytiX, Hombrechti-
kon, Switzerland). The RNA Tubes were incubated for at
least 2 h at room temperature after blood collection to
ensure complete lysis of blood cells and were then
stored at −20 °C until further processing. Before start-
ing the procedure, they were equilibrated to room
temperature. Total RNA > 18 nucleotides (including
miRNA) was purified manually using the PAXgene BloodmiRNA Kit (PreAnalytiX) according to the manufacturer’s
protocol.
miRNA Array
RNA quality and quantity was assessed by capillary elec-
trophoresis using the Fragment Analyzer and Standard/
High sensitivity RNA Analysis kits (Advanced Analytical
Technologies, Ames, IA, U.S.). Total whole blood RNA
of patients with active synovial sarcoma (n = 5) and
healthy controls (n = 5) was then analyzed using an Affy-
metrix GeneChip miRNA Array v. 4.0 (Affymetrix, Santa
Clara, CA, U.S.). 275 ng of total RNA was labeled with
Biotin using a 3DNA Array Detection FlashTag™ Biotin
HSR kit (Genisphere, Hatfield, PA, U.S.) following the
manufacturer’s protocol, being subsequently hybridized
overnight. The GeneChip® miRNA 4.0 arrays, containing
30,424 total mature miRNA probe sets including 2.578
mature human miRNAs and miRNAs of 202 other or-
ganisms, were washed and stained using the Affymetrix
GeneChip Hybridization Wash and Stain Kit and were
then scanned with the Affymetrix GeneChip Scanner
3000 7G (Affymetrix, Santa Clara, CA, U.S.).
Cell culture
The samples of the human synovial sarcoma cell lines
SYO-1 und 1273/99 were a donation from Dr. Marcus
Renner, Institute of Pathology, University of Heidelberg.
SYO-1 synovial sarcoma cells were cultured in Dulbec-
co’s modified minimal essential medium (life technolo-
gies, Carlsbad, CA, U.S.A.) supplemented with 10 % FBS
superior (Biochrom, Berlin, Germany), 100 U/ml Penicillin-
Streptomycin (life technologies) and 0.5 % Sodium Pyru-
vate (Biochrom, Berlin, Germany).
1273/99 synovial sarcoma cells were cultured in F-12
Nutrient mixture (Ham) (life technologies) supplemented
with 10 % FBS superior and 100 U/ml Penicillin-
Streptomycin.
THP-1 cells (human acute monocytic leukemia cell line)
and Jurkat cells (human T lymphocyte cell line) were cul-
tured in RPMI Medium 1640 (with L-Glutamine; life tech-
nologies) supplemented with 10 % FBS superior and 100
U/ml Penicillin-Streptomycin.
RNA Isolation
Total RNA of SYO-1, 1273/99, THP-1 and Jurkat cells
was purified using the miRNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. Total
RNA of tissue sample sections, each with a thickness of
10 μm and a surface area of approximately 250 mm2, was
purified after deparaffinization using the miRNeasy FFPE
Kit (Qiagen) with an extension of the time of incubation
with proteinase K at 56 °C from 15 min to 60 min for
higher RNA yields. The remaining steps were carried out
according to the manufacturer’s protocol. The RNA was
Fricke et al. Molecular Cancer  (2015) 14:151 Page 11 of 13quantified using a Nanodrop 2000 (Thermo Fisher Scien-
tific, Waltham, MA, USA).
Preparation of cDNA
For detection of miRNA expression levels, cDNA syn-
thesis of whole blood RNA, cell RNA and tissue RNA
(275 ng) was carried out using the miScript II RT Kit
(Qiagen) according to the manufacturer’s protocol. The
reverse transcription reaction was incubated for 60 min
at 37 °C, followed by 5 min at 95 °C to inactivate the
miScript Reverse Transcriptase Mix.
For detection of the SS18-SSX1 and SS18-SSX2 fusion
gene transcript in tissue samples, each 275 ng of RNA
was converted to cDNA using the AffinityScript Multi
Temperature cDNA Synthesis Kit (Agilent Technologies,
Santa Clara, CA, USA) according to the manufacturer’s
protocol. The reverse transcription reaction was incu-
bated for 10 min at 25 °C, followed by 1 h at 42 °C and
15 min at 70 °C.
qRT-PCR
For detection of miRNA expression levels, qRT-PCR was
performed using the miScript SYBR Green PCR Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. Briefly, the cycling conditions consisted
of an initial activation step of the HotStarTaq DNA Poly-
merase for 15 min at 95 °C, followed by 45 cycles of de-
naturation for 15 s at 94 °C, annealing for 30 s at 55 °C
and extension for 30 s at 70 °C with fluorescence data
collection being performed during the extension step.
MiScript Primer Assays were purchased from Qiagen.
Ct-values were normalized to RNU6-2B, a frequently
used reference gene [33] and 2-ΔΔCt values [34] were an-
alyzed using Student’s t-test for independent samples.
For detection of the SS18-SSX1 and SS18-SSX2 fusion
gene transcript in tissue samples, qRT-PCR was per-
formed using the Absolute qPCR ROX Mix (Thermo-
Scientific, Waltham, MA, USA) and the following
primers: SS18-SSX1 + FAM (Hs 03024820_ft), SS18-
SSX2 + FAM (Hs03024398_ft) (TaqMan Gene Expres-
sion Assays; Applied Biosystems by life technologies,
Carlsbad, CA, USA) and the GAPDH-Primer Set (GAPDH-
probe 899, GAPDH-875 F und GAPDH 946-R (Eurofins
MWG Operon, Huntsville, AL, USA) as the internal con-
trol. Briefly, the cycling conditions were enzyme activation
at 95 °C for 15 min, followed by 50 cycles of denaturation
at 95 °C for 15 s and annealing/extension at 60 °C for
1 min. Ct-values < 36 were considered as positive.Statistics
For analysis of the miRNA array, CEL-files of the raw data
were produced with Affymetrix GeneChip Command
Console Software Version 4.0. (Affymetrix, Santa Clara,CA, U.S.) Partek Genomics Suite software (Version
6.14.0923; Partek, Inc., St. Louis, MO, USA) was used for
further analysis. CEL-files were imported including control
and interrogating probes, and the arrays were normalized
using quantile normalization. Probeset summarization was
done using Median Polish. Probe values were log2 trans-
formed. In order to detect differential miRNA expression
between the 2 groups, 1-way ANOVA was performed [35]
and Fisher’s Least Significant Difference (LSD) was used
as contrast method.
MultiExperiment Viewer 4.8 was used for hierarchical
clustering of miRNA array data [36]. 2-ΔΔCt and patients’
demographic data and blood counts were compared
using Student’s t-test for independent samples. p-values
were rounded to 4 significant digits; p-values below 0.05
were considered statistically significant.
Additional files
Additional file 1: Demographic patient data and blood count of
patients with active sarcoma and control groups. Demographic
patient data (age, BMI) and blood count (hemoglobin level, platelet
count and leukocyte count) of patients with active synovial sarcoma
compared to healthy donors, patients with synovial sarcoma in remission
and patients with active leiomyosarcoma, MPNST, Ewing sarcoma and
liposarcoma. Data are presented as mean value ± standard error of mean
(SEM). p- values were determined using a Student’s t-test for independent
samples. Hb = Hemoglobin. BMI = Body Mass Index. (PPTX 68 kb)
Additional file 2: Demographic patient data and blood count of
patients with active sarcoma (Individual Cohort (IC)) and control
groups. Demographic patient data (age, BMI) and blood count
(hemoglobin level, platelet count and leukocyte count) of patients with
active synovial sarcoma (Individual Cohort (IC)) compared to healthy
donors and patients with synovial sarcoma in remission. Data are
presented as mean value ± standard error of mean (SEM). p- values were
determined using a Student’s t-test for independent samples. Hb =
Hemoglobin. BMI = Body Mass Index. IC = Independent Cohort. (PPTX
66 kb)
Additional file 3: Disease and therapy status of sarcoma patients.
M0 = localized disease. M1 = metastatic disease. Current chemotherapy/
radiotherapy involves treatment within the last 6 weeks. (PPTX 67 kb)
Additional file 4: Illustration of the miRNA-expression levels of the
two active synovial sarcoma patients who received chemotherapy
(Patient 2 and 3 of the screening cohort of active synovial sarcoma
patients as depicted in Additional file 3) marked with a triangle,
patients receiving anticoagulation (Patient 3 of the screening
cohort of active synovial sarcoma patients and Patient 1 of the
independent cohort of active synovial sarcoma patients as depicted
in Additional file 3) marked in green and patients receiving
radiotherapy/presenting localized disease (Patient 1 of the screening
cohort of active synovial sarcoma patients as depicted in Additional
file 3) marked in red. A, C, E, G, I, K and M include the screening cohort
of active synovial sarcoma patients, B, D, F, H, J, L and N depict the
independent cohort (IC) of synovial sarcoma patients. (JPEG 5044 kb)
Additional file 5: Comparison of whole blood miRNA expression
levels of patients with active synovial sarcoma and miRNA
expression levels of corresponding synovial sarcoma tissue.
MiRNA-expression of patients with synovial sarcoma expressing
SS18-SSX2 are marked in purple. A. miR-99a-5p. B. miR-146b-5p. C.
miR-148b-3p. D. miR-195-5p. E. miR-223-3p. F. miR-500b-3p. G.
miR-505-3p. (JPEG 2837 kb)
Additional file 6: MiRNA expression levels of Jurkat (human
T-lymphocyte cell line) and THP-1 cells (human acute monocytic
Fricke et al. Molecular Cancer  (2015) 14:151 Page 12 of 13leukemia cell line) compared to synovial sarcoma cells (SYO-1
und 1273/99 cell lines). A. miR-99a-5p. B. miR-146b-5p. C.
miR-148b-3p. D. miR-195-5p. E. miR-223-3p. F. miR-500b-3p. G.
miR-505-3p. (JPEG 2926 kb)
Abbreviations
BMI: Body mass Index; CT: Computed Tomography; FISH: Fluorescence In Situ
Hybridization; Hb: Hemoglobin; MiRNA: MicroRNA; MPNST: Malignant
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NF-κB: Nuclear factor κ B; qRT-PCR: quantitative Reverse Transcription -
Polymerase Chain Reaction.
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